Triple therapy in chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2019-29-2-199-206
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Recently, therapeutic options for treatment of chronic obstructive pulmonary disease (COPD) has been significantly extended, mainly due to new double and triple drug combinations in a single inhaler. Double combinations for treatment of COPD include long-term acting beta-2-agonists (LABA)/long-term acting muscarinic antagonists (LAMA) and LABA/inhaled corticosteroids (ICS); a triple combination is a combination of LABA, LAMA and ICS in a single inhaler. A review of consensus statements, national guidelines and recently published data about use of triple therapy in COPD, efficacy and safety of a triple combination is given in the article.
About the Authors
Sergey N. Avdeev
I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia;
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Sergey N. Avdeev, Doctor of Medicine, Professor, Corresponding Member of Russian Academy of Sciences, Head of Department of Pulmonology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University); Head of Clinical Division, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; tel.: (495) 708-35-76;
Trubetskaya ul. 8, build. 2, Moscow, 119991
Orekhovyy bul'var 28, Moscow, 115682
Natal’ya V. Trushenko
I.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia;
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Natal’ya V. Trushenko, Candidate of Medicine, Researcher, Research Center for Monitoring and Control of Respiratory Diseases, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; Assistant Lecturer, Department of Pulmonology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University); tel.: (495) 395-63-93;
Trubetskaya ul. 8, build. 2, Moscow, 119991
Orekhovyy bul'var 28, Moscow, 115682
References
1. Aisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 183-187. https://doi.org/10.2147/COPD.S153770.
2. Barnes P.J., Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 2008; 8 (3): 183-192. https://doi.org/10.1038/nri2254.
3. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2018 Report. Available at: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf
4. Landis S.H., Muellerova H., Mannino D.M. et al. Continuing to confront COPD international patient survey: methods, COPD prevalence, and disease burden in 2012-2013. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 597-611. https://doi.org/10.2147/COPD.S61854.
5. Arkhipov V.V., Arkhipova D.E., Stukalina E.Yu., Lazarev A.A. [Frequency of different phenotypes of chronic obstructive pulmonary disease in Russian Federation: description and therapeutic approaches]. Prakticheskaya pul’monologiya. 2016; (3): 20-25. Available at: https://cyberleninka.ru/article/v/chastota-vstrechaemosti-otdelnyh-fenotipov-hronicheskoy-obstruktivnoy-bolezni-legkih-v-rossiyskoy-federatsii-ih-harakteristiki-i (in Russian).
6. Worth H., Buhl R., Criée C.P. et al. GOLD 2017 treatment pathways in ‘real life’: An analysis of the DACCORD observational study. Respir. Med. 2017; 131: 77-84. https://doi.org/10.1016/j.rmed.2017.08.008.
7. Vestbo J., Vogelmeier C., Small M., Higgins V. Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. Respir. Med. 2014; 108 (5): 729-736. https://doi.org/10.1016/j.rmed.2014.03.002.
8. Simeome J.C., Luthra R., Kaila S. et al. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 12: 73-83. https://doi.org/10.2147/COPD.S122013.
9. Welte T., Miravitlles M., Hernandez P. et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180 (8): 741-750. https://doi.org/10.1164/rccm.200904-0492OC.
10. Singh D., Brooks J., Hagan G. et al. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008; 63 (7): 592-598. https://doi.org/10.1136/thx.2007.087213.
11. Cazzola M., Andò F., Santus P. et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm. Pharmacol. Ther. 2007; 20 (5): 556-561. https://doi.org/10.1016/j.pupt.2006.06.001.
12. Frith P.A., Thompson P.J., Ratnavadivel R. et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015; 70 (6): 519-527. https://doi.org/10.1136/thoraxjnl-2014-206670.
13. Siler T.M., Kerwin E., Sousa A.R. et al. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies. Respir. Med. 2015; 109 (9): 1155-1163. https://doi.org/10.1016/j.rmed.2015.06.006.
14. Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146 (8): 545-555.
15. Sousa A.R., Riley J.H., Church A. et al. The effect of umeclidinium added to inhaled corticosteroid/longacting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study. NPJ Prim. Care Respir. Med. 2016; 26: 16031. https://doi.org/10.1038/npjpcrm.2016.31.
16. Wedzicha J.A., Singh D., Vestbo J. et al. Extrafine beclomethasone/ formoterol in severe COPD patients with history of exacerbations. Respir. Med. 2014; 108 (8): 1153-1162. https://doi.org/10.1016/j.rmed.2014.05.013.
17. Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1 (3): 199-209. https://doi.org/10.1016/S2213-2600(13)70052-3.
18. Miravitlles M., Soler-Cataluña J.J., Calle M. et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch. Bronconeumol. 2012; 48 (7): 247-257. https://doi.org/10.1016/j.arbres.2012.04.001 (in English, Spanish).
19. Miravitlles M., Anzueto A. A new two-step algorithm for the treatment of COPD. Eur. Respir. J. 2017; 49 (2): pii: 1602200. https://doi.org/10.1183/13993003.02200-2016.
20. Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Eng. J. Med. 2018; 378 (18): 1671-1680. https://doi.org/10.1056/NEJMoa1713901.
21. Lipson D.A., Barnacle H., Birk R. et al. FULFIL trial: once-daily triple therapy in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2017; 196 (4): 438-446. https://doi.org/10.1164/rccm.201703-0449OC.
22. Singh D., Corradi M., Spinola M. et al. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Int. J. Chron. Obstruct. Pulmon. Dis. 2017:12: 2917-2928. https://doi.org/10.2147/COPD.S146822.
23. Papi A., Vestbo J., Fabbri L. et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. 2018; 391 (10125): 1076-1084. https://doi.org/10.1016/S0140-6736(18)30206-X.
24. Short P.M., Williamson P.A., Elder D.H.J. et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest. 2012; 141 (1): 81-86. https://doi.org/10.1378/chest.11-0038.
25. Kolsum U., Damera G., Pham T.H. et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J. Allergy Clin. Immunol. 2017; 140 (4): 1181-1184.e7. https://doi.org/10.1016/j.jaci.2017.04.027.
26. Kolsum U., Donaldson G.C., Singh R. et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir. Res. 2017; 18 (1): 88. https://doi.org/10.1186/s12931-017-0570-5.
27. Pascoe S., Locantore N., Dransfield M.T. et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 2015; 3 (6): 435-442. https://doi.org/10.1016/S2213-2600(15)00106-X.
28. Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2016; 71 (2): 118-125. https://doi.org/10.1136/thoraxjnl-2015-207021.
29. Siddiqui S.H., Guasconi A., Vestbo J. et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015; 192 (4): 523-525. https://doi.org/10.1164/rccm.201502-0235LE.
30. Siddiqui S.H., Pavord I.D., Barnes N.C. et al. Blood eosinophils (EOS) are a biomarker of COPD exacerbation reduction with inhaled corticosteroids (ICS): an across-trials modelbased approach. Eur. Respir. J. 2016; 48 (Suppl. 60): OA1763.
31. Watz H., Tetzlaff K., Wouters E.F. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir. Med. 2016; 4 (5): 390-398. https://doi.org/10.1016/S2213-2600(16)00100-4.
32. Vestbo J., Papi A., Corradi M. et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017; 389 (10082): 1919-1929. https://doi.org/10.1016/S0140-6736(17)30188-5.
33. Barnes N.C., Sharma R., Lettis S., Calverley P.M. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur. Respir. J. 2016; 47 (5): 1374-1382. https://doi.org/10.1183/13993003.01370-2015.
34. Singh D., Kolsum U., Brightling C.E. et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur. Respir. J. 2014; 44 (6): 1697-1700. https://doi.org/10.1183/09031936.00162414.
35. Calverley P.M., Magnussen H., Miravitlles M., Wedzicha J.A. Triple therapy in COPD: What we know and what we don't. J. COPD. 2017; 14 (6): 648-662. https://doi.org/10.1080/15412555.2017.1389875.
36. Ferguson G.T., Rabe K.F., Martinez F.J. et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir. Med. 2018; 6 (10): 747-758. https://doi.org/10.1016/S2213-2600(18)30327-8.
37. Vestbo J., Anderson J.A., Brook R.D. et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a doubleblind randomised controlled trial. Lancet. 2016; 387 (10030): 1817-1826. https://doi.org/10.1016/S0140-6736(16)30069-1.
38. Singh D., Corradi M., Spinola M. et al. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. NPJ Prim. Care Respir. Med. 2016; 26: 16030. https://doi.org/10.1038/npjpcrm.2016.30.
39. Dransfield M.T., Bourbeau J., Jones P.W. et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir. Med. 2013; 1 (3): 210-223. https://doi.org/10.1016/S2213-2600(13)70040-7.
40. Singh D., Roche N., Halpin D. et al. Current controversies in the pharmacological treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2016; 194 (5): 541-549. https://doi.org/10.1164/rccm.201606-1179PP.
41. Crim C., Dransfield M.T., Bourbeau J. et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann. Am. Thorac. Soc. 2015; 12 (1): 27-34. https://doi.org/10.1513/AnnalsATS.201409-413OC.
42. Karur P., Singh D. Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention. Ann. Trans. Med. 2016; 4 (24): 531. https://doi.org/ 10.21037/atm.2016.11.58.
43. Singh D. Single inhaler triple therapy with extrafine beclomethasone, formoterol and glycopyrronium for the treatment of chronic obstructive pulmonary disease. Expert Opin. Pharmacother. 2018; 19 (11): 1279-1287. https://doi.org/10.1080/14656566.2018.1498841.
Review
For citations:
Avdeev S.N., Trushenko N.V. Triple therapy in chronic obstructive pulmonary disease. PULMONOLOGIYA. 2019;29(2):199-206. (In Russ.) https://doi.org/10.18093/0869-0189-2019-29-2-199-206
Views:
6432
ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)
ISSN 2541-9617 (Online)
Email this article 